Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
NCT07387354 · Thomas Jefferson University · PHASE1/PHASE2 · withdrawn · last registry update 2026-08-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “FDA requested significant changes to the study protocol” | – | Registry record, Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against JAK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (withdrawn): Incepta Pharmaceuticals Ltd, Baricitinib + Placebo (NCT05056558)
- 2026-10-27Phase 3 first posted: AbbVie, Upadacitinib + Placebo for Upadacitinib (NCT07896434)
- 2026-10-16Results posted on the registry: Julie Nangia, Ruxolitinib + Placebo (for Ruxolitinib) (NCT02928978)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-10-06Results posted on the registry: Bristol-Myers Squibb, SAR302503 (TG101348) (NCT00724334)
- 2026-09-16Also stopped (terminated): Ryvu Therapeutics SA, RVU120 + Ruxolitinib (NCT06397313)
- 2026-09-09Also stopped (withdrawn): Vanderbilt University Medical Center, Baricitinib 4 MG + Placebo (NCT05858515)
- 2026-08-19Phase 3 first posted: AbbVie, Upadacitinib + Placebo (NCT07772492)
- 2026-08-13Results posted on the registry: AbbVie, ABT-494 (NCT02782663)
- 2026-08-11Results posted on the registry: Bristol-Myers Squibb, SAR302503 + Placebo (NCT01437787)
- 2026-08-11Also stopped (terminated): Bristol-Myers Squibb, SAR302503 + Placebo (NCT01437787)
- 2026-08-11Results posted on the registry: Eli Lilly and Company, Baricitinib (NCT05074420)
- 2026-08-11Also stopped (terminated): Eli Lilly and Company, Baricitinib (NCT05074420)
- 2026-08-04Results posted on the registry: Syntara, PXS-5505 (NCT04676529)
- 2026-07-27Results posted on the registry: Alfasigma S.p.A., Filgotinib + Placebo to match filgotinib (NCT03025308)
- 2026-07-23Phase 3 first posted: Merck Sharp & Dohme LLC, Bomedemstat + Ruxolitinib (NCT07722611)
- 2026-07-16Results posted on the registry: Bristol-Myers Squibb, SAR302503 (NCT01523171)
- 2026-07-16Also stopped (terminated): Bristol-Myers Squibb, SAR302503 (NCT01523171)
- 2026-07-15Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Ruxolitinib (NCT05998408)
- 2026-07-15Also stopped (terminated): Alfasigma S.p.A., Filgotinib + Filgotinib (NCT06222034)
- 2026-07-10Results posted on the registry: Eli Lilly and Company, Baricitinib + TNF Inhibitor (NCT04086745)
- 2026-07-09Results posted on the registry: Massachusetts General Hospital, Ruxolitinib (NCT03427866)
- 2026-07-07Results posted on the registry: Tu Dan, Identify any dose-limiting toxicity (DLT) when ruxolitinib is administered to NSCLC cachexia patients. (NCT04906746)
- 2026-06-30Results posted on the registry: Massachusetts General Hospital, Baricitinib (NCT05189106)
- 2026-06-29Results posted on the registry: University of Texas Southwestern Medical Center, Tofacitinib 10mg + Temozolomide (NCT05326464)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision